0.418
2.94%
+0.0119
After Hours:
.3862
-0.0318
-7.61%
Theriva Biologics Inc stock is currently priced at $0.418, with a 24-hour trading volume of 35,704.
It has seen a +2.94% increased in the last 24 hours and a -5.00% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.3958 pivot point. If it approaches the $0.4202 resistance level, significant changes may occur.
Previous Close:
$0.4061
Open:
$0.4
24h Volume:
35,704
Market Cap:
$7.17M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-19.20M
1W Performance:
+1.96%
1M Performance:
-5.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
GlobeNewswire Inc.
Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica
GlobeNewswire Inc.
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
GlobeNewswire Inc.
Theriva™ Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del ejercicio 2023
GlobeNewswire Inc.
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
GlobeNewswire Inc.
Theriva Biologics Inc Stock (TOVX) Financials Data
Theriva Biologics Inc (TOVX) Net Income 2024
TOVX net income (TTM) was -$18.35 million for the quarter ending December 31, 2023, a +6.78% increase year-over-year.
Theriva Biologics Inc (TOVX) Cash Flow 2024
TOVX recorded a free cash flow (TTM) of -$19.20 million for the quarter ending December 31, 2023, a 0.00% decrease year-over-year.
Theriva Biologics Inc (TOVX) Earnings per Share 2024
TOVX earnings per share (TTM) was -$1.16 for the quarter ending December 31, 2023, a +12.78% growth year-over-year.
About Theriva Biologics Inc
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):